Immunic (IMUX) Free Cash Flow (2013 - 2026)
Immunic (IMUX) posted Free Cash Flow of -$17.3 million for Q1 2026, up 10.31% sequentially from -$19.3 million in Q4 2025, and up 20.71% YoY from -$14.3 million in Q1 2025.
Immunic (IMUX) Free Cash Flow (2013 - 2026) Analysis & Trends
Immunic has reported Free Cash Flow for 14 years, with the latest figure at -$17.3 million in Q1 2026.
- Quarterly Free Cash Flow rose 20.71% year-over-year to -$17.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$81.4 million (up 1.7% YoY) and the FY2025 annual result came in at -$86.0 million, down 1.1% from the prior year.
- Free Cash Flow grew to -$17.3 million in Q1 2026 per IMUX's latest filing, from -$19.3 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$13.7 million in Q3 2022 and troughed at -$24.6 million in Q2 2025.
- A 5-year average of -$19.1 million and a median of -$19.6 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow soared 45.59% in 2022, then tumbled 61.82% in 2024.
- Over 5 years, Free Cash Flow stood at -$15.1 million in 2022, then rose by 6.03% to -$14.2 million in 2023, then sank by 61.82% to -$23.0 million in 2024, then increased by 16.0% to -$19.3 million in 2025, then advanced by 10.31% to -$17.3 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$17.3 million, -$19.3 million, and -$20.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Immunic | 682.77 Mn | 682.77 Mn | - | -31.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.25 Mn |
| Jun 30, 2026 | -31.25 Mn |
| Mar 31, 2026 | -17.30 Mn |
| Mar 31, 2026 | -17.30 Mn |
| Dec 31, 2025 | -19.29 Mn |
| Dec 31, 2025 | -19.29 Mn |
| Sep 30, 2025 | -20.21 Mn |
| Sep 30, 2025 | -20.21 Mn |
| Jun 30, 2025 | -24.65 Mn |
| Jun 30, 2025 | -24.65 Mn |
| Mar 31, 2025 | -21.82 Mn |
| Mar 31, 2025 | -21.82 Mn |
| Dec 31, 2024 | -22.97 Mn |
| Dec 31, 2024 | -22.97 Mn |
| Sep 30, 2024 | -20.85 Mn |
| Sep 30, 2024 | -20.85 Mn |
| Jun 30, 2024 | -17.22 Mn |
| Jun 30, 2024 | -17.22 Mn |
| Mar 31, 2024 | -24.00 Mn |
| Mar 31, 2024 | -24.00 Mn |